![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | ZRANB3 | Human | (-)-epigallocatechin 3-gallate | multiple interactions | EXP | | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZRANB3 mRNA | CTD | PMID:22079256 | ZRANB3 | Human | 1,2-dichloroethane | decreases expression | ISO | Zranb3 (Mus musculus) | 6480464 | ethylene dichloride results in decreased expression of ZRANB3 mRNA | CTD | PMID:28960355 | ZRANB3 | Human | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Zranb3 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of ZRANB3 mRNA | CTD | PMID:21570461 | ZRANB3 | Human | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of ZRANB3 mRNA | CTD | PMID:20106945 and PMID:21632981 | ZRANB3 | Human | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | EXP | | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ZRANB3 mRNA | CTD | PMID:28628672 | ZRANB3 | Human | 4,4'-sulfonyldiphenol | multiple interactions | EXP | | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ZRANB3 mRNA | CTD | PMID:28628672 | ZRANB3 | Human | 4-hydroxyphenyl retinamide | increases expression | ISO | Zranb3 (Mus musculus) | 6480464 | Fenretinide results in increased expression of ZRANB3 mRNA | CTD | PMID:28973697 | ZRANB3 | Human | acrylamide | decreases expression | ISO | Zranb3 (Mus musculus) | 6480464 | Acrylamide results in decreased expression of ZRANB3 mRNA | CTD | PMID:30807115 | ZRANB3 | Human | aflatoxin B1 | affects expression | EXP | | 6480464 | Aflatoxin B1 affects the expression of ZRANB3 protein | CTD | PMID:20106945 | ZRANB3 | Human | aflatoxin B1 | decreases expression | EXP | | 6480464 | Aflatoxin B1 results in decreased expression of ZRANB3 mRNA | CTD | PMID:21641981 and PMID:22100608 | ZRANB3 | Human | aflatoxin B1 | decreases expression | ISO | Zranb3 (Mus musculus) | 6480464 | Aflatoxin B1 results in decreased expression of ZRANB3 mRNA | CTD | PMID:19770486 | ZRANB3 | Human | all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of ZRANB3 mRNA | CTD | PMID:33167477 | ZRANB3 | Human | antirheumatic drug | increases expression | EXP | | 6480464 | Antirheumatic Agents results in increased expression of ZRANB3 mRNA | CTD | PMID:24449571 | ZRANB3 | Human | aristolochic acid A | decreases expression | EXP | | 6480464 | aristolochic acid I results in decreased expression of ZRANB3 mRNA | CTD | PMID:33212167 | ZRANB3 | Human | arsenous acid | decreases expression | ISO | Zranb3 (Mus musculus) | 6480464 | Arsenic Trioxide results in decreased expression of ZRANB3 mRNA | CTD | PMID:35676786 | ZRANB3 | Human | benzo[a]pyrene | decreases expression | ISO | Zranb3 (Mus musculus) | 6480464 | Benzo(a)pyrene results in decreased expression of ZRANB3 mRNA | CTD | PMID:21715664 | ZRANB3 | Human | benzo[a]pyrene | decreases methylation | ISO | Zranb3 (Mus musculus) | 6480464 | Benzo(a)pyrene results in decreased methylation of ZRANB3 intron | CTD | PMID:27901495 | ZRANB3 | Human | benzo[a]pyrene | decreases expression | EXP | | 6480464 | Benzo(a)pyrene results in decreased expression of ZRANB3 mRNA | CTD | PMID:20106945 more ... | ZRANB3 | Human | benzo[a]pyrene diol epoxide I | decreases expression | EXP | | 6480464 | 7 more ... | CTD | PMID:26238291 | ZRANB3 | Human | bisphenol A | decreases expression | ISO | Zranb3 (Rattus norvegicus) | 6480464 | bisphenol A results in decreased expression of ZRANB3 mRNA | CTD | PMID:25181051 | ZRANB3 | Human | bisphenol A | decreases expression | ISO | Zranb3 (Mus musculus) | 6480464 | bisphenol A results in decreased expression of ZRANB3 mRNA | CTD | PMID:32156529 | ZRANB3 | Human | cadmium dichloride | decreases expression | EXP | | 6480464 | Cadmium Chloride results in decreased expression of ZRANB3 mRNA | CTD | PMID:38568856 | ZRANB3 | Human | caffeine | decreases phosphorylation | EXP | | 6480464 | Caffeine results in decreased phosphorylation of ZRANB3 protein | CTD | PMID:35688186 | ZRANB3 | Human | carbon nanotube | increases expression | ISO | Zranb3 (Mus musculus) | 6480464 | Nanotubes more ... | CTD | PMID:25554681 | ZRANB3 | Human | carbon nanotube | decreases expression | ISO | Zranb3 (Mus musculus) | 6480464 | Nanotubes and Carbon results in decreased expression of ZRANB3 mRNA | CTD | PMID:25620056 | ZRANB3 | Human | CGP 52608 | multiple interactions | EXP | | 6480464 | CGP 52608 promotes the reaction [RORA protein binds to ZRANB3 gene] | CTD | PMID:28238834 | ZRANB3 | Human | chlorpyrifos | decreases expression | ISO | Zranb3 (Mus musculus) | 6480464 | Chlorpyrifos results in decreased expression of ZRANB3 mRNA | CTD | PMID:37019170 | ZRANB3 | Human | cisplatin | decreases expression | EXP | | 6480464 | Cisplatin results in decreased expression of ZRANB3 mRNA | CTD | PMID:27392435 and PMID:27594783 | ZRANB3 | Human | cisplatin | multiple interactions | EXP | | 6480464 | [Cisplatin co-treated with jinfukang] results in decreased expression of ZRANB3 mRNA | CTD | PMID:27392435 | ZRANB3 | Human | clofibrate | increases expression | ISO | Zranb3 (Mus musculus) | 6480464 | Clofibrate results in increased expression of ZRANB3 mRNA | CTD | PMID:23811191 | ZRANB3 | Human | coumarin | decreases phosphorylation | EXP | | 6480464 | coumarin results in decreased phosphorylation of ZRANB3 protein | CTD | PMID:35688186 | ZRANB3 | Human | cyclosporin A | decreases expression | EXP | | 6480464 | Cyclosporine results in decreased expression of ZRANB3 mRNA | CTD | PMID:20106945 | ZRANB3 | Human | dexamethasone | multiple interactions | EXP | | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ZRANB3 mRNA | CTD | PMID:28628672 | ZRANB3 | Human | diarsenic trioxide | decreases expression | ISO | Zranb3 (Mus musculus) | 6480464 | Arsenic Trioxide results in decreased expression of ZRANB3 mRNA | CTD | PMID:35676786 | ZRANB3 | Human | dibutyl phthalate | decreases expression | ISO | Zranb3 (Mus musculus) | 6480464 | Dibutyl Phthalate results in decreased expression of ZRANB3 mRNA | CTD | PMID:21266533 | ZRANB3 | Human | dicrotophos | decreases expression | EXP | | 6480464 | dicrotophos results in decreased expression of ZRANB3 mRNA | CTD | PMID:28302478 | ZRANB3 | Human | dorsomorphin | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | ZRANB3 | Human | endosulfan | increases expression | ISO | Zranb3 (Rattus norvegicus) | 6480464 | Endosulfan results in increased expression of ZRANB3 mRNA | CTD | PMID:29391264 | ZRANB3 | Human | ethyl methanesulfonate | decreases expression | EXP | | 6480464 | Ethyl Methanesulfonate results in decreased expression of ZRANB3 mRNA | CTD | PMID:23649840 | ZRANB3 | Human | flutamide | increases expression | ISO | Zranb3 (Rattus norvegicus) | 6480464 | Flutamide results in increased expression of ZRANB3 mRNA | CTD | PMID:24793618 | ZRANB3 | Human | folic acid | decreases expression | ISO | Zranb3 (Mus musculus) | 6480464 | Folic Acid results in decreased expression of ZRANB3 mRNA | CTD | PMID:25629700 | ZRANB3 | Human | formaldehyde | decreases expression | EXP | | 6480464 | Formaldehyde results in decreased expression of ZRANB3 mRNA | CTD | PMID:23649840 | ZRANB3 | Human | gentamycin | decreases expression | ISO | Zranb3 (Rattus norvegicus) | 6480464 | Gentamicins results in decreased expression of ZRANB3 mRNA | CTD | PMID:33387578 | ZRANB3 | Human | indometacin | multiple interactions | EXP | | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ZRANB3 mRNA | CTD | PMID:28628672 | ZRANB3 | Human | isoprenaline | increases expression | ISO | Zranb3 (Mus musculus) | 6480464 | Isoproterenol results in increased expression of ZRANB3 mRNA | CTD | PMID:20003209 | ZRANB3 | Human | methyl methanesulfonate | decreases expression | EXP | | 6480464 | Methyl Methanesulfonate results in decreased expression of ZRANB3 mRNA | CTD | PMID:23649840 | ZRANB3 | Human | methylmercury chloride | decreases expression | EXP | | 6480464 | methylmercuric chloride results in decreased expression of ZRANB3 mRNA | CTD | PMID:28001369 | ZRANB3 | Human | N,N-diethyl-m-toluamide | multiple interactions | ISO | Zranb3 (Rattus norvegicus) | 6480464 | [Permethrin co-treated with DEET] results in increased methylation of ZRANB3 gene | CTD | PMID:33148267 | ZRANB3 | Human | N-Nitrosopyrrolidine | decreases expression | EXP | | 6480464 | N-Nitrosopyrrolidine results in decreased expression of ZRANB3 mRNA | CTD | PMID:32234424 | ZRANB3 | Human | O-methyleugenol | decreases expression | EXP | | 6480464 | methyleugenol results in decreased expression of ZRANB3 mRNA | CTD | PMID:32234424 | ZRANB3 | Human | ozone | multiple interactions | ISO | Zranb3 (Mus musculus) | 6480464 | [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in increased expression of ZRANB3 mRNA and [Air Pollutants results in increased abundance of Ozone] which results in increased expression of ZRANB3 mRNA | CTD | PMID:34911549 | ZRANB3 | Human | panobinostat | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZRANB3 mRNA | CTD | PMID:27188386 | ZRANB3 | Human | paracetamol | affects expression | ISO | Zranb3 (Mus musculus) | 6480464 | Acetaminophen affects the expression of ZRANB3 mRNA | CTD | PMID:17562736 | ZRANB3 | Human | paracetamol | increases expression | ISO | Zranb3 (Rattus norvegicus) | 6480464 | Acetaminophen results in increased expression of ZRANB3 mRNA | CTD | PMID:33387578 | ZRANB3 | Human | paracetamol | decreases expression | EXP | | 6480464 | Acetaminophen results in decreased expression of ZRANB3 mRNA | CTD | PMID:29067470 | ZRANB3 | Human | permethrin | multiple interactions | ISO | Zranb3 (Rattus norvegicus) | 6480464 | [Permethrin co-treated with DEET] results in increased methylation of ZRANB3 gene | CTD | PMID:33148267 | ZRANB3 | Human | phenylmercury acetate | decreases expression | EXP | | 6480464 | Phenylmercuric Acetate results in decreased expression of ZRANB3 mRNA | CTD | PMID:26272509 | ZRANB3 | Human | phenylmercury acetate | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZRANB3 mRNA | CTD | PMID:27188386 | ZRANB3 | Human | pirinixic acid | increases expression | ISO | Zranb3 (Mus musculus) | 6480464 | pirinixic acid results in increased expression of ZRANB3 mRNA | CTD | PMID:23811191 | ZRANB3 | Human | potassium chromate | decreases expression | EXP | | 6480464 | potassium chromate(VI) results in decreased expression of ZRANB3 mRNA | CTD | PMID:22079256 | ZRANB3 | Human | potassium chromate | multiple interactions | EXP | | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZRANB3 mRNA | CTD | PMID:22079256 | ZRANB3 | Human | resveratrol | multiple interactions | EXP | | 6480464 | [Plant Extracts co-treated with Resveratrol] results in increased expression of ZRANB3 mRNA | CTD | PMID:23557933 | ZRANB3 | Human | SB 431542 | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | ZRANB3 | Human | silicon dioxide | increases expression | ISO | Zranb3 (Mus musculus) | 6480464 | Silicon Dioxide results in increased expression of ZRANB3 mRNA | CTD | PMID:29341224 | ZRANB3 | Human | sodium arsenite | decreases expression | ISO | Zranb3 (Mus musculus) | 6480464 | sodium arsenite results in decreased expression of ZRANB3 mRNA | CTD | PMID:37682722 | ZRANB3 | Human | sunitinib | decreases expression | EXP | | 6480464 | Sunitinib results in decreased expression of ZRANB3 mRNA | CTD | PMID:31533062 | ZRANB3 | Human | thioacetamide | decreases expression | ISO | Zranb3 (Rattus norvegicus) | 6480464 | Thioacetamide results in decreased expression of ZRANB3 mRNA | CTD | PMID:34492290 | ZRANB3 | Human | titanium dioxide | increases expression | ISO | Zranb3 (Mus musculus) | 6480464 | titanium dioxide results in increased expression of ZRANB3 mRNA | CTD | PMID:19464567 more ... | ZRANB3 | Human | tremolite asbestos | increases expression | ISO | Zranb3 (Mus musculus) | 6480464 | tremolite results in increased expression of ZRANB3 mRNA | CTD | PMID:29279043 | ZRANB3 | Human | trimellitic anhydride | increases expression | ISO | Zranb3 (Mus musculus) | 6480464 | trimellitic anhydride results in increased expression of ZRANB3 mRNA | CTD | PMID:19042947 | ZRANB3 | Human | tungsten | decreases expression | ISO | Zranb3 (Mus musculus) | 6480464 | Tungsten results in decreased expression of ZRANB3 mRNA | CTD | PMID:30912803 | ZRANB3 | Human | urethane | decreases expression | EXP | | 6480464 | Urethane results in decreased expression of ZRANB3 mRNA | CTD | PMID:28818685 | ZRANB3 | Human | valproic acid | affects expression | EXP | | 6480464 | Valproic Acid affects the expression of ZRANB3 mRNA | CTD | PMID:25979313 | ZRANB3 | Human | valproic acid | decreases expression | EXP | | 6480464 | Valproic Acid results in decreased expression of ZRANB3 mRNA | CTD | PMID:23179753 more ... | ZRANB3 | Human | valproic acid | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZRANB3 mRNA | CTD | PMID:27188386 | |